Iryna Drozd Lexicon Pharmaceuticals ( NASDAQ: LXRX ) said the FDA has declined to approve its drug Zynquista, also known as sotagliflozin, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease, or CKD, issuing the company a Complete.